株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

眼科治療薬:技術および世界市場

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 121843
出版日 ページ情報 英文 111 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
眼科治療薬:技術および世界市場 Ophthalmic Therapeutic Drugs: Technologies and Global Markets
出版日: 2015年07月31日 ページ情報: 英文 111 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の眼科治療薬市場は、2014年に123億米ドルの規模に達し、2019年までCAGR 9.1%のペースで成長を続け、190億米ドルの規模に達すると予想されています。

当レポートでは、様々な眼病のための治療薬を概説し、2013年および2014年の市場実績と2019年までの成長予測、地域別動向、市場に参入する競合企業のプロファイルなどをまとめてお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 網膜疾患:加齢性黄斑変性症

  • 網膜疾患
  • 加齢性黄斑変性症(AMD)
  • 市場規模
  • 市場成長促進因子
  • アンメットクリニカルニーズの領域
  • ウェット型 AMDの新しい治療法
  • ドライ型 AMDの新しい治療法
  • 将来の市場規模
  • まとめ

第4章 緑内障

  • 疾患のサブタイプ
  • 診断率
  • 治療方法
  • 市場規模
  • 市場成長促進因子
  • アンメットクリニカルニーズの領域
  • 新しい薬物送達方法と剤形
  • 新しい治療法
  • 初期段階の創薬
  • 将来の市場規模
  • まとめ

第5章 ドライアイ

  • 診断率
  • 治療法
  • 市場規模
  • 市場成長促進因子
  • アンメットクリニカルニーズの領域
  • 新しい治療法
  • 新しい製剤設計
  • 初期段階の創薬
  • 将来の市場規模
  • まとめ

第6章 ブドウ膜炎

  • 診断率
  • 治療法
  • 市場規模
  • 市場成長促進因子
  • アンメットクリニカルニーズの領域
  • 新しい治療法
  • 新しい製剤設計
  • 初期段階の創薬
  • 将来の市場規模
  • まとめ

第7章 最新市場動向

  • 企業間提携およびライセンス契約
  • M&A

第8章 企業プロファイル

第9章 付録I:頭字語・略語

第10章 付録?:参考文献

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM031D

The global ophthalmic therapeutic drug market was valued at $12.3 billion in 2014. This market is expected to reach $19 billion by 2019, with a compound annual growth rate (CAGR) of 9.1% from 2014 to 2019.

This report provides:

  • An overview of the global market for ophthalmic therapeutic drugs.
  • Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
  • Investigation of one of the most important market drivers, combination therapies.
  • Learn how healthcare awareness and emerging middle classes in countries such as India, China, Brazil and Russia are providing market opportunities.
  • Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.
  • Analysis of these major players to help define the specific product strategies which they are employing.

image1

REPORT SCOPE

SCOPE OF REPORT

This report on ophthalmic therapeutics drugs provides a brief description of the current status of the industry and recent developments. The report analyzes the market trends, and identifies key therapeutic and geographical challenges and rising opportunities in the developed and developing world. Finally, it will provide insights into new developments into ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.

ANALYST'S CREDENTIALS

Dr. C. L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company, and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C. L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE REPORT
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT,2013-2019 ($ MILLIONS)

CHAPTER 3 RETINAL DISEASES: AGE-RELATED MACULAR DEGENERATION

  • RETINAL DISEASE
  • FIGURE 1 STRUCTURE OF THE EYE
  • AGE-RELATED MACULAR DEGENERATION (AMD)
  • FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS)
    • DISEASE SUBTYPES
      • Early AMD
      • Intermediate AMD
      • Late-Stage AMD
        • Dry AMD
        • Wet AMD
      • FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD
    • DIAGNOSIS RATE
    • CURRENT TREATMENT
    • TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD
  • CURRENT MARKET SIZE
  • TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019 ($ MILLIONS)
  • TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • MARKET DRIVERS
  • AREAS OF UNMET CLINICAL NEED
  • TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT
  • NEW THERAPIES FOR WET AMD
    • CONBERCEPT (CHENGDU KANGHONG PHARMACEUTICAL GROUP)
    • LAMPALIZUMAB (GENENTECH)
    • BROLUCIZUMAB (ALCON)
    • FOVISTA + ANTI-VEGF COMBINATION (ALCON/OPHTHOTECH)
    • TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE III
    • TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II
    • TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I
    • NEW TREATMENTS FOR DRY AMD
    • TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III
    • TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II
    • NEW THERAPIES
      • Emixustat Hydrochloride (Acucela/Otsuka)
      • FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS
      • GSK-933776 (GSK)
  • FUTURE MARKET SIZE
  • TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY

CHAPTER 4 GLAUCOMA

  • FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • DISEASE SUBTYPES
    • PRIMARY OPEN-ANGLE GLAUCOMA
    • PRIMARY ANGLE-CLOSURE GLAUCOMA
    • FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA
  • DIAGNOSIS RATE
  • CURRENT TREATMENT
  • TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS
    • MONOTHERAPY
    • TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY
    • FIXED DOSE COMBINATIONS
    • TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE COMBINATIONS
      • Prescription Patterns
      • FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%)
      • FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%)
      • FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%)
  • CURRENT MARKET SIZE
  • TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
  • TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • MARKET DRIVERS
  • AREAS OF UNMET CLINICAL NEED
  • TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT
  • NEW DELIVERY APPROACHES AND FORMULATIONS
  • TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III
  • TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II
  • TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I
  • NEW THERAPIES
    • RHO KINASE (ROCK) INHIBITORS
    • GLANATEC (KOWA)
    • RHOPRESSA AND ROCLATAN (AERIE PHARMACEUTICALS)
    • FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS' RHOPRESSA
    • TABLE 23 ROCK INHIBITORS IN DEVELOPMENT
    • GENE SILENCING AGENTS
    • TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT
    • BAMOSIRAN (SYLENTIS SA)
    • IST-0036 (ISARNA THERAPEUTICS GMBH)
    • QPI-1007 (QUARK PHARMACEUTICALS)
  • EARLY-STAGE DRUG DEVELOPMENT
    • ANTI-AMYLOID BETA AGENTS
    • CANNABINOIDS
    • TRANSIENT RECEPTOR POTENTIAL VANILLOID ISOFORM 4 (TRPV4)
  • FUTURE MARKET SIZE
  • TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY

CHAPTER 5 DRY EYE SYNDROME

  • FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • DIAGNOSIS RATE
  • CURRENT TREATMENT
  • TABLE 27 PRODUCTS APPROVED TO TREAT DES
  • CURRENT MARKET SIZE
  • TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
  • TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • MARKET DRIVERS
  • AREAS OF UNMET CLINICAL NEED
  • TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT
  • NEW THERAPIES
    • CYCLOKAT/IKERVIS (SANTEN PHARMACEUTICAL)
    • LIFITEGRAST (SHIRE)
    • REFRESH (ACTAVIS)
    • EBI-005 (ELEVEN BIOTHERAPEUTICS)
    • EGP-435 (EYEGATE PHARMA/VALEANT PHARMACEUTICALS)
    • MIM-D3 (MIMETOGEN)
    • TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III
    • TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II
  • NEW FORMULATIONS
  • EARLY-STAGE DRUG DEVELOPMENT
  • FUTURE MARKET SIZE
  • TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY

CHAPTER 6 UVEITIS

  • FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • DIAGNOSIS RATE
  • CURRENT TREATMENT
  • TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS
  • CURRENT MARKET SIZE
  • TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
  • TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • MARKET DRIVERS
  • AREAS OF UNMET CLINICAL NEED
  • TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT
  • NEW THERAPIES
    • GEVOKIZUMAB (XOMA)
    • SIROLIMUS (SANTEN PHARMACEUTICAL)
    • TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III
    • TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II
    • TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I
  • NEW FORMULATIONS
    • EGP-437 (EYEGATE PHARMA/ VALENAT PHARMACUETICALS)
  • EARLY-STAGE DRUG DEVELOPMENT
  • FUTURE MARKET SIZE 8
  • TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY

CHAPTER 7 RECENT MARKET ACTIVITY

  • ALLIANCES AND LICENSING DEALS
  • FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014 (NO. OF DEALS)
  • FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY, 2007-2014 (NO. OF DEALS)
  • TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY 2015 ($ MILLIONS)
  • TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014 ($ MILLIONS)
    • ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY
    • FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY, 2007-2014 (NO. OF DEALS)
    • TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 ($ MILLIONS)
    • TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE, 2007-2014 ($ MILLIONS)
    • TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • MERGERS AND ACQUISITIONS
  • FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 2007-2014 (NUMBER)
  • TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE, 2007- JULY 2015 ($ MILLIONS)

CHAPTER 8 COMPANY PROFILES

  • LEADING PHARMACEUTICALS COMPANIES
    • ACTAVIS (FORMERLY ALLERGAN)
    • ALCON
    • F. HOFFMANN-LA ROCHE
    • MERCK & CO.
    • SHIRE PLC
    • SUMITOMO DAINIPPON PHARMA
    • VALEANT PHARMACEUTICALS
  • LEADING SPECIALIST PHARMA COMPANIES
    • ACUCELA
    • AERIE PHARMACEUTICALS
    • INOTEK PHARMACEUTICALS
    • LUX BIOSCIENCES
    • MOLECULAR PARTNERS AG
    • OPTHERION PHARMACEUTICALS
    • PSIVIDA CORPORATION
    • REGENERON PHARMACEUTICALS
    • RESOLVYX PHARMACEUTICALS
    • SANTEN PHARMACEUTICAL CO. LTD
    • SYLENTIS S.A.
  • LEADING GENERIC AND BIOSIMILAR MANUFACTURER
    • AKORN INC.

CHAPTER 9 APPENDIX I: ACRONYMS

  • ACRONYMS

CHAPTER 10 APPENDIX II: REFERENCES

  • AMD REFERENCES
  • GLAUCOMA REFERENCES
  • DRY EYE SYNDROME REFERENCES
  • UVEITIS REFERENCES
  • WEBSITES
  • WEBLINKS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD
  • TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019 ($ MILLIONS)
  • TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT
  • TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE III
  • TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II
  • TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I
  • TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III
  • TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II
  • TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS
  • TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY
  • TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE COMBINATIONS
  • TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT
  • TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III
  • TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II
  • TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I
  • TABLE 23 ROCK INHIBITORS IN DEVELOPMENT
  • TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT
  • TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 PRODUCTS APPROVED TO TREAT DES
  • TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT
  • TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III
  • TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II
  • TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS
  • TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
  • TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT
  • TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III
  • TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II
  • TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I
  • TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY 2015 ($ MILLIONS)
  • TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE, 2007-2014 ($ MILLIONS)
  • TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE, 2007- JULY 2015 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT,2013-2019 ($ MILLIONS)
  • FIGURE 1 STRUCTURE OF THE EYE
  • FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD
  • FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS
  • FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA
  • FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%)
  • FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%)
  • FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%)
  • FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
  • FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS' RHOPRESSA
  • FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
  • FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS)
  • FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
  • FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY COMPANY, 2014 (%)
  • FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014 (NO. OF DEALS)
  • FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY, 2007-2014 (NO. OF DEALS)
  • FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY, 2007-2014 (NO. OF DEALS)
  • FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 2007-2014 (NUMBER)
Back to Top